Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study

Akhondzadeh, Shahin; Malek-Hosseini, Mojgan; Ghoreishi, Abolfazl; Raznahan, Maedeh; Rezazadeh, Shamsali

doi:10.1016/j.pnpbp.2008.08.020

Cited by 65 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Administration of the 5-HT 2C/2A agonist m-CPP caused deterioration of positive psychotic symptoms in schizophrenia, an effect that could be prevented by the 5-HT 2C/2A blocker ritanserin (Abi-Saab et al, 2002). Moreover, ritanserin in combination with risperidone showed significant superiority over risperidone alone in decreasing negative symptoms in schizophrenia patients (Akhondzadeh et al, 2008). These results suggest that 5-HT 2C blockade may actually have beneficial effects on positive, negative, and cognitive symptoms in schizophrenia (Meltzer et al, 2003).…”

Section: Role Of Other 5-ht Receptorsmentioning

confidence: 84%

“…clozapine, olanzapine, sertindole) roughly corresponds with their potential to produce weight gain rather than with potential antipsychotic activity. However, some clinical data did suggest that augmentation with the 5-HT 2C/2A antagonists ritanserin and mianserin may have some beneficial effects especially on negative and cognitive symptoms in schizophrenia Meltzer et al, 2003;Akhondzadeh et al, 2008). (Harmar et al, 2009;www.iuphar-db.org .…”

Section: Role Of Other 5-ht Receptorsmentioning

confidence: 99%

See 1 more Smart Citation

Serotonin and Schizophrenia

Quednow

Geyer

Halberstadt

2010

Handbook of Behavioral Neuroscience

View full text Add to dashboard Cite

Although the serotonin hypothesis of schizophrenia is one of the oldest neurochemical hypotheses on the pathogenesis of this disease, it is still highly topical. The concept of how the serotonin system is involved in the origin and progress of schizophrenia has considerably changed over the past decades. Therefore, the present work will give an overview about the development and the current directions of the serotonin hypothesis of schizophrenia. In this regard, we will discuss the phenomenology of hallucinogenic drug action, model psychosis and translational research, post-mortem studies on receptors and transporters, imaging studies, antipsychotic drug action, neuroendocrine challenge studies, platelet and cerebrospinal fluid data, genetic association studies, developmental aspects, and the cross-talk between the glutamate and the serotonin system. In sum, there are several lines of evidence suggesting that the serotonin system plays a major role in the pathogenesis of at least a subpopulation of schizophrenia patients. Further studies are needed to better characterize patients whose psychotic symptoms are suspected to have a serotonergic origin. Serotonin and Schizophrenia AbstractAlthough the serotonin hypothesis of schizophrenia is one of the oldest neurochemical hypotheses on the pathogenesis of this disease, it is still highly topical. The concept of how the serotonin system is involved in the origin and progress of schizophrenia has considerably changed over the past decades.Therefore, the present work will give an overview about the development and the current directions of the serotonin hypothesis of schizophrenia. In this regard, we will discuss the phenomenology of hallucinogenic drug action, model psychosis and translational research, post-mortem studies on receptors and transporters, imaging studies, antipsychotic drug action, neuroendocrine challenge studies, platelet and cerebrospinal fluid data, genetic association studies, developmental aspects, and the cross-talk between the glutamate and the serotonin system. In sum, there are several lines of evidence suggesting that the serotonin system plays a major role in the pathogenesis of at least a subpopulation of schizophrenia patients. Further studies are needed to better characterize patients whose psychotic symptoms are suspected to have a serotonergic origin.3

show abstract

Section: Role Of Other 5-ht Receptorsmentioning

confidence: 84%

Section: Role Of Other 5-ht Receptorsmentioning

confidence: 99%

Serotonin and Schizophrenia

Quednow

Geyer

Halberstadt

2010

Handbook of Behavioral Neuroscience

View full text Add to dashboard Cite

show abstract

“…Patients and involved nurses were asked to immediately inform the research team about any unexpected symptom or complaint during the course of the trial. All participants were systematically asked for adverse events at each visit through open‐ended questioning followed by a complete side effects checklist (a 25‐item checklist; Akhondzadeh et al, ; Ghaleiha et al, ).…”

Section: Methodsmentioning

confidence: 99%

Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study

Rezaei

Mesgarpour²,

Jeddian

et al. 2017

Hum. Psychopharmacol Clin Exp

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ritanserin was reported to be effective in treating acutely psychotic patients with schizophrenia in a small, open trial (Wiesel et al 1994) and to potentiate risperidone, in a larger placebo-controlled, randomized, doubleblind trial (Akhondzadeh et al 2008). The latter finding is surprising because risperidone, 6 mg/day, should have been sufficient to fully block 5-HT 2A receptors.…”

Section: Nmda Receptor Non-competitive Antagonist-induced Hyperlocomomentioning

confidence: 99%

The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

2011

View full text Add to dashboard Cite

show abstract

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study

Cited by 65 publications

References 20 publications

Serotonin and Schizophrenia

Serotonin and Schizophrenia

Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study

The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

Contact Info

Product

Resources

About